SOURCE: ViaDerma, Inc.

November 30, 2016 17:49 ET

ViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions

Clinical Tests Show Dramatic Success of ViaDerma's Proprietary Delivery System Combined with FDA Approved Drugs for Wound Healing with Localized Wound Treatment -- This Leads to Early-Stage discussions with two Pharmaceutical Companies to Private Label Viabecline for Distribution in Europe, Asia, the Middle East, and North Africa

LOS ANGELES, CA--(Marketwired - November 30, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today several patients have had significant treatment success with the use of its innovative transdermal system for the delivery of its FDA registered drug, Viabecline. Significant results have been achieved in just 10 days of treatment using ViaDerma's proprietary transdermal delivery system. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas. The "Patent Pending Transdermal System" can deliver medications and nutrients into the body through the skin. For example, a deep wound with the hip bone exposed, had significant healing results, at the Dar Al Zahraa Hospital in Tripoli, Lebanon, after just 10 days. ViaDerma is seeing amazing penetration and absorption with localized wound treatment. "We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido," said CEO Dr. Christopher Otiko.

Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.

Market for the following Drugs:
Topical antibiotics - $6 billion/year
Toenail antifungal drugs - $3 billion/year
Diabetic amputations - $3 billion/year
Global acne - $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis - $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema - $2.5 billion in 2014

ViaDerma has had Clinical success in a very short time frame. We see the use of many drugs along with our "Proprietary Transdermal Delivery System" for the treatment and continuing studies looks very promising and demonstrates efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community. We are also in early-stage discussion with two companies to private label Viabecline for distribution in the Middle East, Asia and North Africa, and Europe," said Dr. Christopher Otiko, ViaDerma's founder and CEO.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, Patent application using the combination of CBDs and THC with the delivery system was filed in 2014. The use of CBDs is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit:

Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.

Contact Information